Infinity Pharma

infinitypharma.com.br

Overcoming barriers, pushing boundaries and bringing the latest to the masterful market is the goal of Infinity Pharma®. A brand that has in its DNA the innovative spirit and evolution as fundamental pieces, capable of transforming the segment leading brand, reference in prevention and innovation of individualized treatment, into a business model with an identity that represents a new vision for the future with infinite possibilities. Inspired by infinity, the company begins a new cycle and aims to exceed the expectations of master consumers, doctors and pharmacists, combining quality, research and technology in new proposals for individualization, with unique assets. With brand-leading experience, Infinity Pharma® has established itself as a company specializing in individualized treatment, reference in prevention and innovation in products, services and concepts for health professionals and the master market.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

FILING BUZZER: LEARN WHY BIOTECHNOLOGY VALUE FUND L P JUST PURCHASED INFINITY PHARMACEUTICALS, INC STAKE?

Pharamaceutical | December 30, 2016

news image

Biotechnology Value Fund L P filed with the SEC SC 13G/A form for Infinity Pharmaceuticals, Inc. The form can be accessed here: 000092189516006421. As reported in Biotechnology Value Fund L P’s form, the filler as of late owns 15.8% or 7,860,808 shares of the Health Care–company....

Read More

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

news image

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More

CIVICA RX PARTNERS WITH THERMO FISHER SCIENTIFIC TO DEVELOP AND MANUFACTURE DRUGS WITH A HISTORY OF DRUG SHORTAGES

Business Wire Press Releases | January 16, 2020

news image

Today announced it has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway. By working with Thermo Fisher to develop Civica-owned Abbreviated New Drug Applications (ANDAs), Civica will secure the manufacture of certain essential medications, further mitigating the risk of drug shortages in the future. This partnership has an initial seven-year term and represents a key component of Civica’s man...

Read More

OCUPHIRE PHARMA ANNOUNCES IN-LICENSE OF PHASE 2 ORAL SMALL MOLECULE DRUG CANDIDATE FOR DIABETIC RETINOPATHY

Business Wire | January 22, 2020

news image

Ocuphire Pharma, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders, today announced that it has entered into an agreement with Apexian Pharmaceuticals, Inc., granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications. APX3330 is a first-in-class, orally-adminis...

Read More
news image

FILING BUZZER: LEARN WHY BIOTECHNOLOGY VALUE FUND L P JUST PURCHASED INFINITY PHARMACEUTICALS, INC STAKE?

Pharamaceutical | December 30, 2016

Biotechnology Value Fund L P filed with the SEC SC 13G/A form for Infinity Pharmaceuticals, Inc. The form can be accessed here: 000092189516006421. As reported in Biotechnology Value Fund L P’s form, the filler as of late owns 15.8% or 7,860,808 shares of the Health Care–company....

Read More
news image

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More
news image

CIVICA RX PARTNERS WITH THERMO FISHER SCIENTIFIC TO DEVELOP AND MANUFACTURE DRUGS WITH A HISTORY OF DRUG SHORTAGES

Business Wire Press Releases | January 16, 2020

Today announced it has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway. By working with Thermo Fisher to develop Civica-owned Abbreviated New Drug Applications (ANDAs), Civica will secure the manufacture of certain essential medications, further mitigating the risk of drug shortages in the future. This partnership has an initial seven-year term and represents a key component of Civica’s man...

Read More
news image

OCUPHIRE PHARMA ANNOUNCES IN-LICENSE OF PHASE 2 ORAL SMALL MOLECULE DRUG CANDIDATE FOR DIABETIC RETINOPATHY

Business Wire | January 22, 2020

Ocuphire Pharma, Inc., a clinical-stage pharmaceutical company focused on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders, today announced that it has entered into an agreement with Apexian Pharmaceuticals, Inc., granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications. APX3330 is a first-in-class, orally-adminis...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us